The Recall Desk
HighFDA (Drugs)·D-1145-2022·Announced 2022-06-22

Medroxyprogesterone Acetate Injectable Suspension Recalled for Sterility Concerns

Sun Pharmaceutical is recalling 4,625 syringes of Medroxyprogesterone Acetate Injectable Suspension (Lot HAC1951A) due to lack of assurance of sterility. The affected medication was distributed nationwide.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: FDA Class II recall with documented lack of sterility assurance in an injectable medication. No illnesses or injuries have been reported, and no hospitalizations are documented, making this a risk-of-harm product without reported injury, consistent with High severity per the rubric.

Plain-English summary

Sun Pharmaceutical Industries Inc is recalling Medroxyprogesterone Acetate Injectable Suspension, USP, 150 mg/mL in 1 mL prefilled syringes (Lot HAC1951A, expiration 06/2023, NDC 62756-091-40) due to lack of assurance of sterility.

Approximately 4,625 syringes were distributed nationwide in the United States. Patients who may have received medication from this lot should contact their healthcare provider or pharmacy for guidance regarding use of the affected product.

The recalled product

Product
MEDROXYPROGESTERONE ACETATE (MEDROXYPROGESTERONE ACETATE)
Brand
MEDROXYPROGESTERONE ACETATE
Manufacturer
SUN PHARMACEUTICAL INDUSTRIES INC
Hazard
  • contamination-risk
  • sterility-failure

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot #: HAC1951A
  • Exp 06/2023

Distribution

Distributed nationwide across the United States.

Same brand · MEDROXYPROGESTERONE ACETATE